Os Therapies Inc (OSTX) — SEC Filings
Os Therapies Inc (OSTX) — 44 SEC filings. Latest: 424B5 (Apr 2, 2026). Includes 23 8-K, 5 10-Q, 5 S-1.
View Os Therapies Inc on SEC EDGAR
Overview
Os Therapies Inc (OSTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B5 filed on Apr 2, 2026: OS Therapies Inc. filed a 424B5 form on April 2, 2026, related to a prospectus supplement. The filing details are associated with CIK 0001795091 and accession number 0001213900-26-039456. The company's mailing and business address is 15825 Shady Grove Road, Suite 135, Rockville, MD 20850.
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 1 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Os Therapies Inc is neutral.
Filing Type Overview
Os Therapies Inc (OSTX) has filed 1 424B5, 5 10-Q, 23 8-K, 2 DEFA14A, 2 DEF 14A, 5 S-1, 1 10-K, 4 S-1/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of OSTX's 43 recent filings, 3 were flagged as high-risk, 22 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$15,293,011 |
| Cash Position | $1,876,626 |
| Total Assets | $8,953,251 |
| Total Debt | $4,245,351 |
Key Executives
- Paul A. Romness, MPH
- Spencer G. Feldman, Esq.
- Paul A. Romness
- Spencer G. Feldman
- Dr. David J. E. Smith
Industry Context
OS Therapies Inc. operates in the highly competitive and capital-intensive biotechnology sector, characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovation, intellectual property protection, and the ability to secure substantial funding for clinical trials and commercialization. The industry is driven by advancements in therapeutic areas like oncology, where the acquired HER2 assets are relevant.
Top Tags
equity-sale (10) · pharmaceuticals (8) · material-agreement (7) · sec-filing (7) · 8-k (5) · ipo (5) · pharmaceutical (4) · 10-Q (4) · quarterly-report (4) · filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Prospectus Supplement Size | 464170 | Size of the primary document filed |
| Net Loss | $15,293,011 | for the nine months ended September 30, 2025, a 159.5% increase from $5,891,704 in 2024 |
| Cash | $1,876,626 | as of September 30, 2025, down from $5,533,527 at December 31, 2024 |
| Research & Development Expenses | $7,563,988 | for the nine months ended September 30, 2025, a 284.2% increase from $1,968,591 in 2024 |
| General & Administrative Expenses | $9,153,821 | for the nine months ended September 30, 2025, a 387.2% increase from $1,878,831 in 2024 |
| Fair Value of HER2 Assets Acquisition | $6,864,438 | completed on April 9, 2025 |
| Common Stock Shares Outstanding | 35,214,352 | as of November 14, 2025 |
| Total Stockholders' Equity | $3,637,195 | as of September 30, 2025, improved from a deficit of $(3,266,538) at December 31, 2024 |
| Accumulated Deficit | $53,725,386 | as of September 30, 2025, increased from $38,432,375 at December 31, 2024 |
| SEC File Number | 001-42195 | Identifies the company's filing history with the SEC |
| IRS Employer Identification No. | 82-5118368 | Company's tax identification number |
| Number of directors to be elected | 6 | Serving until the 2026 annual meeting |
| Minimum percentage of common stock to be issued to Ayala Pharmaceuticals, Inc. | 20% | Exceeding 20% of common stock outstanding as of April 9, 2025 |
| Current authorized shares of common stock | 50 million | Proposed to increase to 150 million |
| Proposed authorized shares of common stock | 150 million | A 200% increase from 50 million |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Os Therapies Inc (OSTX)?
Os Therapies Inc has 44 recent SEC filings from Jan 2024 to Apr 2026, including 23 8-K, 5 10-Q, 5 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of OSTX filings?
Across 44 filings, the sentiment breakdown is: 1 bearish, 41 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Os Therapies Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Os Therapies Inc (OSTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Os Therapies Inc?
Key financial highlights from Os Therapies Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for OSTX?
The investment thesis for OSTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Os Therapies Inc?
Key executives identified across Os Therapies Inc's filings include Paul A. Romness, MPH, Spencer G. Feldman, Esq., Paul A. Romness, Spencer G. Feldman, Dr. David J. E. Smith.
What are the main risk factors for Os Therapies Inc stock?
Of OSTX's 43 assessed filings, 3 were flagged high-risk, 22 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Os Therapies Inc?
Forward guidance and predictions for Os Therapies Inc are extracted from SEC filings as they are enriched.